Dr. Alok K Mishra | Oncology investigation Award | Best Researcher Award

Dr. Alok K Mishra, UMASS CHAN MEDICAL SCHOOL, United States

Alok K Mishra, a molecular immunologist and biochemist based in Worcester, MA, brings over 5 years of post-doctoral experience to the field. His expertise lies in immune-oncology, CRISPR screening, and cancer drug target discovery, particularly focusing on ovarian cancer and macrophage interactions within the tumor microenvironment. With a Ph.D. from the Central Drug Research Institute, India, Alok’s research delves into genome-scale CRISPR screening and immunological techniques to unravel novel drug targets for cancer immunotherapy. He holds patents in targeting glycosylphosphatidylinositol pathway proteins for ovarian cancer treatment and has pending NIH R01 grants. Alok’s extensive publication record includes impactful research articles and editorial roles in prestigious journals. He is an active member of several scientific societies and serves as an academic editor for PLOS ONE.

Professional Profile:

Orcid

Education :

lok K Mishra holds a Ph.D. in Life Sciences from the Central Drug Research Institute, India, where his research focused on unraveling the role of two-component systems in mycobacteria. This foundational work laid the groundwork for his subsequent contributions to molecular immunology. Prior to his doctoral studies, Alok completed a Master of Science in Biotechnology from the Indian Institute of Technology, Mumbai, where he honed his skills in molecular biology and biotechnological applications. He obtained his Bachelor of Science in Life Sciences from Delhi University, India, laying the groundwork for his academic journey in the field of life sciences.

Experience:

As a Postdoctoral Associate at the University of Massachusetts Medical School, Alok K Mishra specializes in conducting cutting-edge research in the field of immune-oncology. Leveraging his expertise in molecular immunology and biochemistry, he focuses on unraveling the complexities of immune responses in cancer. Alok’s work involves exploring innovative approaches, such as CRISPR screening and cancer drug target discovery, to advance our understanding of immune-oncology and develop novel therapies for cancer treatment. Through his dedication and commitment to scientific inquiry, he contributes significantly to the ongoing efforts in cancer research at the University of Massachusetts Medical School.

Research Interest:

Alok’s research focuses on molecular immunology, particularly in immune-oncology and CRISPR screenings. He specializes in genome-scale CRISPR screening and immunological techniques to identify novel drug targets for cancer immunotherapy. His work in ovarian cancer and macrophage-cancer cell interactions is particularly noteworthy

Publication Top Notes:

1.”Unlocking the enigma of phenotypic drug tolerance: Mechanisms and emerging therapeutic strategies” in Biochimie (2024), cited by a journal article.

2.”Assessment of Rocaglates and Targeted Derivatives as Selective Inhibitors of Glioblastoma Stem Cells” in a preprint from 2023, cited by another preprint.

3.”Inhibiting the GPI Transamidase Subunit GPAA1 Abolishes CD24 Surface Localization and Enhances Macrophage-Mediated Phagocytosis of Ovarian Cancer Cells” in a preprint from 2023, cited by a preprint.

4.”Advancing cellular immunotherapy with macrophages” in Life Sciences (2023), cited by a journal article.

5.”Next-Generation Sequencing Technology: Current Trends and Advancements” in Biology (2023), cited by a journal article.